Assessing REMS: Risk Management's Key Question -- Do The Programs Work?
This article was originally published in RPM Report
Executive Summary
The first stage of REMS implementation from March 2008 until December 2009 was relatively easy. FDA and drug sponsors leaqrned how to adapt existing communications programs and techniques to deliver new safety messages. Now both the agency and the sponsors are moving into new territory: evaluating REMS. Both are grappling with the challenge of how to show that programs are working.
You may also be interested in...
Opioid REMS: Committee Rejects FDA Proposal, But Sponsors Should Embrace It
The combined Anesthetic & Life Support Drugs and Drug Safety & Risk Management advisory committees voted strongly (25-10) against FDA’s proposed classwide educational REMS for long-acting opioids; but the vote does not stop the process. In fact, FDA may have achieved much of what it set out to do by just by proposing a class REMS in the area.
Opioid REMS: Committee Rejects FDA Proposal, But Sponsors Should Embrace It
The combined Anesthetic & Life Support Drugs and Drug Safety & Risk Management advisory committees voted strongly (25-10) against FDA’s proposed classwide educational REMS for long-acting opioids; but the vote does not stop the process. In fact, FDA may have achieved much of what it set out to do by just by proposing a class REMS in the area.
InVentiv Sees More Opportunities To Serve Pharma As Private Vs. Public Company
Private equity firm Thomas H. Lee Partners agrees to acquire contract sales and services company inVentiv Health for $1.1 billion.